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Abstract Chronic osteomyelitis is a multifaceted bacterial
infection with common features. It absolutely requires sur-
gery for remission. The duration and form of concomitant
administration of antibiotic agents for adult patients is still
based on expert opinion. The traditional recommendation of
6–12 weeks of antibiotic therapy, where, for at least the first
2–6 weeks, antibiotics should be administered intravenous-
ly, is more and more challenged in favor of an oral antibiotic
treatment with selected agents from the start. There is no
evidence that the total duration of antibiotic therapy for
more than 4–6 weeks improves outcome, when compared
with shorter regimens. Hopefully, the future will show ran-
domized trials in the adult population, allowing optimal
timing of surgical and medical therapy and sparing of un-
necessary prescription, with concomitant development of
antibiotic resistance. External advice from an expert team
with combined surgeons and infectious disease physicians
may help to reduce antibiotic consumption in a cost-
effective way.
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Introduction
Chronic bone infection requires combined surgical and
medical treatment. It demands long-lasting antibiotic treat-
ments [1], which leads to a high burden on patients and
hospitals in terms of morbidity and additional costs [2].
Various reports indicate a minimal cost of $15,000 and a
median 2-week prolongation of hospital stay [3]. A persis-
tent mechanic disablement can be witnessed among patients,
which is often underreported.
In contrast to other fields of infectiology, the adequate
administration route and duration of antibiotic agents in
chronic osteomyelitis are not based on randomized trials or
other forms of evidence. They rely on expert opinion and
some indirect information from animal studies or in vitro
experiments. Moreover, many surgeons and physicians tend
to administer antimicrobials for longer periods, in order to do
something to prevent recurrences, even if their approaches are
not supported by expert opinion. These excesses probably
further contribute to the emergence and spread of multiresist-
ant pathogens [4]. Traditionally, a 6- to 12-week course of
antibiotic therapy is recommended [4, 5•] in association with
surgery, where antibiotics are given intravenously for the first
2–4 weeks. In contrast, recent years have seen ongoing re-
search to reduce and simplify the antibiotic treatment of
osteomyelitis, especially among the pediatric population [6••].
This review gives an overview of and focuses on new
insights into the antibiotic treatment of chronic osteomyeli-
tis. Special features such as pathogenesis or diagnosis,
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prevention [4], implant-related bone infections, osteomyeli-
tis accompanying septic arthritis, vertebral spondylodiscitis,
mandibular osteomyelitis, tuberculosis, fungal bone infec-
tions, and pediatric acute osteomyelitis are exempt or only
very briefly mentioned.
Definition and Microbiology
Osteomyelitis is an infection that can be limited to a single
portion of bone or can involve several regions, such as
marrow, cortex, periosteum, and surrounding soft tissue
[2]. Strictly speaking, osteomyelitis implicates affection of
bone and marrow. The literature lacks an internationally
accepted definition of chronic osteomyelitis [1]. As for any
infection, acute, subacute, and chronic [2] are the headings
of big groups [7] but are not very useful in clinical practice.
A commonly accepted definition requires a minimal symp-
tom duration of 6 weeks to 3 months. Several surgical
classifications have been proposed. Among them, the
Cierny–Mader classification [8] for long-bone osteomyelitis
or the PEDIS classification for diabetic foot osteomyelitis
are the most frequently reported. Generally, surgeons under-
stand chronic osteomyelitis as an infection requiring sur-
gery, with already established sequestra or bone deformities.
Infection is almost exclusively of bacterial origin and is
much less often due to fungi (intravenous drug abusers [9]
or skull osteomyelitis [10]) or parasites (e.g., echinococco-
sis). Among all bacteria and types of osteomyelitis except
for the jaw, Staphylococcus aureus dominates [2, 11•], fol-
lowed by streptococci and Gram-negative pathogens [12]. In
sickle-cell disease-associated bone necrosis and subsequent
osteomyelitis [13], the hallmark is Gram-negative pathogens
[14]—for example, Salmonella spp [2]. Polymicrobial in-
fection is frequent in trauma [15] and long-lasting ulcer-
ations [16]. Anaerobes are rare [17], and coagulase-negative
staphylococci are retrieved almost exclusively in implant-
related osteomyelitis [11•].
Pathogenesis
Bacteria adhere to bone matrix via receptors to fibronectin
and other structural proteins by developing a biofilm [11•,
18]. Biofilms are the hallmark of implant-related osteomy-
elitis but are also important in the absence of a foreign body
[19, 20••]. In biofilms, pathogens undergo complex meta-
bolic changes and become less susceptible not only to the
immune system, but also to antibiotics [21]. For cell-wall-
active antibiotics to be effective in biofilms, 100 to 1,000
times the standard concentration is often required [22].
Additionally, the biofilm inhibits the activity of mononucle-
ar cells, T and B lymphocytes, and chemotactic
responsiveness, thus adversely acting on both cytotoxic
and humoral defense responses [23]. On a macroscopic
level, patchy ischemic bone necrosis occurs when the
inflammation occludes vascular tunnels. Segments of
bone devoid of blood supply can become separated
and are called sequestrae [2]. At the infarction edge,
there is reactive hyperemia with increased osteoclastic
activity [2]. This activity produces bone loss. Mean-
while, bone apposition occurs—in some cases, exuber-
antly—causing periosteal apposition and new bone
formation, named involucrae [2].
Diagnosis
Clinical signs and standard radiographs are suggestive for
diagnosis, but no noninvasive test can definitively exclude
osteomyelitis [24]. The ultimate proof requires growth of
the same pathogens in several, at least two, bone samples
[11•]. Bacteremic disease is rare, and the use of serum
antistreptolysin-O-titers for serological diagnosis of inva-
sive β-hemolytic streptococci is seldom reliable [25]. The
value of pathogen identification with bone surface swabs is
far from being excellent [26, 27]. Radiological signs in
standard X-rays are numerous, but only very few are sug-
gestive of osteomyelitis: sinus tract or the radiological evi-
dence of sequesters and involucres.
Treatment
Chronic osteomyelitis is a surgical disease [2, 28]. For
chronic osteomyelitis, antibiotics alone are very rarely suc-
cessful, because of the biofilm and sequester formation,
which they cannot penetrate, or only very little. Without
adequate debridement, chronic osteomyelitis does not re-
spond to antibiotic regimens, no matter what the antibiotic
choice or the duration of therapy is. Antibiotic administra-
tion without surgery may eradicate infection only for some
exceptions: childhood osteomyelitis, spondylodiscitis, tu-
berculous osteomyelitis, and in selected cases, diabetic toe
osteomyelitis. On the other hand, lack of systemic antibi-
otics [29] yields higher failure rates, highlighting an inde-
pendent benefit of concomitant antibiotic therapy.
Surgical Treatment
The optimal management includes sequestrectomy, resec-
tion of scarred and infected bone as well as soft tissue [2, 8],
obliteration of dead space, appropriate bone mechanical
stability, adequate soft-tissue coverage, and restoration of
an effective blood supply [2]. The debridement is usually
aggressive and as complete as possible [30]. If the stability
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of the bone is compromised, a two-stage procedure might be
required [31]. The first stage consists of extensive debride-
ment, dead space management with antibiotic-containing
beads or cement (Fig. 1), bone stabilization with external
fixation, and coverage with dressings. After 2–3 weeks of
antibiotic treatment comes the second stage: new debride-
ment, removal of the beads or cement, filling in of the dead
space with bone graft, bone stabilization with internal fixa-
tion (plate and/or intramedullary nail), and soft-tissue cov-
erage. A small dead space is left unchanged if the soft-tissue
coverage is good. Large dead spaces are filled to reduce the
likelihood of continued infection and stability loss. If a
cavity cannot be filled by surrounding soft tissue, a local
muscle flap [17] or free tissue transfer obliterates the space.
Autologous bone grafts usually enhance stability after 6–
8 weeks. The Ilizarov technique may bridge bone defects as
long as 15 cm by continuous traction that can be started
10 days after implantation of the device. Coverage with a
vacuum-assisted closure dressing is discouraged by some
surgeons or simply performed by others [32]. Amputation is
infrequent for long-bone osteomyelitis [33], in contrast to
the diabetic foot.
Hyperbaric Oxygen Therapy
Hyperbaric oxygen therapy consumes very substantial
resources [34]. It is said to provide oxygen to promote
collagen production, angiogenesis, and osteogenesis [24,
35]. Several authors have suggested that adjunctive hyper-
baric oxygen might be useful in human chronic osteomye-
litis, even if the results are not consistent [24].
Antibiotic Treatment
Whereas expert opinion and scientific evidence are rich for
hematogenous childhood [6••] or implant-related osteomy-
elitis [36], the optimal antibiotic duration and administration
form postdebridement for implant-free osteomyelitis among
adults remains unknown [1, 2, 15, 37••]. Different case
series express different durations without comparison within
[1, 15, 37••] and between the reports, and international
consensus guidelines are lacking [1].
Parenteral Antibiotic Therapy
In former times, experts usually recommended an intrave-
nous (IV) therapy for 4 [28] to 6 weeks [2, 15, 38, 39],
followed by an oral course of additional weeks or months
[40]. The rationale for a prolonged IV course was elevated
serum concentrations, according to expert opinion. Today,
this opinion has rather switched for IV treatment during the
initial 2 weeks [41]. Without doubt, bone penetration of
antibiotic agents in parenteral administration is good and
bioavailability per definition 100 % [42]. At the same time,
IV medication should be limited as far as possible to save
unnecessary costs, prevent catheter-related complications,
and increase patient and nursing comfort. The estimated
proportion of complications attributed to prolonged IV
course ranges around 15 % [37••, 39]. Recent retrospective
data suggest that regimens with an early switch to oral
antibiotics are as effective as prolonged parenteral regimens
[10, 20••, 43]. A Cochrane review in 2009 included eight
trials comparing oral versus IV antibiotics for chronic oste-
omyelitis in adults. There was no statistically significant
difference in the remission rate at 12 months follow-up,
but the rate of adverse events was significantly higher with
IV administration [37••]. The authors of this article per-
formed a retrospective analysis at their center, with a min-
imal follow-up of 2 years after treatment. Among 49
episodes of implant-free chronic osteomyelitis, 20 % re-
curred. However, in multivariate logistic regression analy-
sis, 1 week of IV therapy had the same remission as 2–
3 weeks or more than 3 weeks [5•]. Several antibiotic agents
proved clinical efficacy upon oral intake: quinolones [12,
Fig. 1 Left: Standard X-ray of
a chronic osteomyelitis of the
tibia. The bone is irregular in
shape with involvement of the
intramedullary canal and corti-
cal extension. Right: Lateral
view of the same case, showing
cortical fenestration and inser-
tion of gentamicin beads for
treatment
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44], linezolid, metronidazole, clindamycin, and fusidic acid
combined with rifampin [20••, 38]. These drugs have an oral
bioavailability of over 90 % [45•].
Duration of Antibiotic Therapy
As a general principle, the duration of antibiotic administra-
tion does not depend on the pathogen, with few exceptions:
osteomyelitis with pathogens for which the literature pro-
vides long-lasting antibiotic treatments (tuberculosis [2, 46],
other mycobacteria such as in buruli ulcer [47], fungi [9], Q
fever [48], nocardiosis [49], or brucellosis [50]).
Total duration of antibiotic treatment, concomitant to sur-
gery, can probably be limited to 6 weeks [20••]. To our best
knowledge, only one paper from 1985 really attributes an
unacceptable high risk of treatment failure, when antibiotics
are administered for less than 4 weeks [51]. Besides this
exception, there are no clinical studies or documented records
indicating the superiority of the 4- to 6-week course over
shorter durations [5•, 15, 20••, 52]. Nonrandomized trials of
longer courses of intravenous or oral antibiotics (6 months or
more) do not suggest any improvement, as compared with
6 weeks of therapy [20••, 24]. As a clinical example, Eyi-
chukwu et al. reported arrest of chronic osteomyelitis after
surgery and a short-term sensitivity-based IV course of 2–
3 days, followed by oral administration [53]. In their recent
review regarding duration of antibiotic treatment for osteomy-
elitis, Haidar et al. listed small individual reports in animals
and humans that obtained remissions with antibiotic durations
ranging from 1 to 4 weeks [15]. In the aforementioned retro-
spective analysis in Geneva among 49 patients with chronic
osteomyelitis, 4 weeks of total antibiotic treatment had the
same outcome as 4–6 weeks, 7–12 weeks, or more than
12 weeks [5•]. Unfortunately, in today’s practice, long post-
surgical oral durations are still frequent [54, 55], ranging from
6 [1, 44] to 10 [53] months or 2 years [1].
Choice of the Antimicrobial Agent
Antimicrobials are based on the susceptibility of the isolated
pathogen, bone penetration, and oral bioavailability (Table 1).
Single-agent antibiotic therapy is usually adequate, and better
pharmacokinetic and -dynamic properties in vitro do not need
to show a direct correlation with clinical outcome.
Ideally, the agent should have bactericidal activity
against slow-growing and biofilm-producing bacteria.
Rifampin fulfils these criteria for staphylococci, al-
though the classical indication for combined rifampin
is staphylococcal implant infection. Nevertheless, rifam-
pin can also be used for implant-free osteomyelitis
[20••]. It can penetrate phagocytes and kill intracellular
bacteria [56] but may lead to the rapid emergence of
rifampin-resistant staphylococci during monotherapy
[11•]. Different antibiotics, such as co-trimoxazole, fusi-
dic acid, tigecycline, daptomycin, linezolid, dalbavancin,
quinupristin/dalfopristin, minocycline, and quinolones,
have been used in combination as a panel [11•, 20••].
The efficacy of many of these possible combinations is
not established in vivo. For instance, the combination of
rifampin with lincosamides (clindamyin [57], macro-
lides) or moxifloxacin is uncertain in humans [11•].
Doses of rifampin ranging from 1×600 mg [20••] to
2×450 mg to 2×600 mg are used in routine practice in
several parts of the world. In contrast to rodents, in
which higher doses yielded some better cure rates, no
prospective randomized trials exist in humans. The
authors of this article and other experts [20••] consider
600 mg daily as sufficient.
Beta-lactam antibiotics can be used intravenously. As a
group, this large class of antibiotics has one important
drawback—that is, low oral bioavailability, together with a
low intraosseous penetration [38, 58].
Since the bone penetration of vancomycin is only
about 15 %–30 % of the serum concentration, minimal
serum through levels of 20–25 mg/ml is believed to
treat bone infections best [59]. In continuous perfusion,
the changes in serum concentrations are much lower
than in intermittent application. The target concentra-
tions are achieved more quickly with fewer adverse
drug effects [59]. However, continuous perfusion does
not guarantee a better outcome in term of remission
[60]. Teicoplanin is available in Europe and elsewhere,
but not in the United States. For bone infections, a high
dose of serum concentrations appears necessary, but the
ideal serum through level or daily dose remains un-
known. LeFrock et al. used doses of 6–12 mg/kg to
treat bone and joint infections [61].
Daptomycin depolarizes membranes and yields a rap-
id, dose-dependent bactericidal effect. It is available
only in parenteral form and is administered once a day
at a dose of 6–8 mg/kg. This makes it suitable for an
outpatient treatment. Clinicians should keep in mind that
emergence of a daptomycin-resistant S. aureus isolate
during treatment of initially daptomycin-susceptible
MRSA osteomyelitis has been described [62]. Trials
with higher doses up to 10 mg/kg are ongoing to
overcome this problem.
Tigecycline belongs to the glycylcyclines, a further de-
velopment of tetracycline antibiotics with a five times
higher affinity to the target. It is available only in parenteral
form: charging dose of 100 mg, followed by 50 mg bid
intravenously. Today, it has to be considered as an experi-
mental drug for osteo-articular infections [63].
Aminoglycosides are less active in synovial fluid or in
bone [64]. Furthermore, staphylococcal small-colony var-
iants, a hallmark of chronic pretreated osteo-articular S.
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aureus infections, are generally resistant to aminoglycosides
[64]. However, in desperate situations and in low-income
countries, aminoglycosides might be an option.
Linezolid inhibits ribosomal protein synthesis and
can be administered parenterally or orally at a dose
of 600 mg bid. It is bacteriostatic with no cross-
resistance to other antibiotics and is essentially anti-
Gram-positive. Due to its excellent bioavailability of
100 %, it is a good choice for outpatient treatments
[65]. Nevertheless, it also features some inconvenien-
ces: Besides an expensive price, it is associated with
reversible bone marrow suppression, particularly
thrombopenia, for an administration of more than
2 weeks. Optic neuropathy and nonreversible peripher-
al neuropathy have been reported in 2 % −4 % [66] of
patients with prolonged administration. A severe sero-
tonin syndrome in co-medication with certain antide-
pressive drugs, such as monoamine oxidase inhibitors,
has been described [67].
Co-trimoxazole is an inexpensive bactericidal folate an-
tagonist. Clinical experience shows that this molecule can
heal small soft-tissue infections [68]. However, it has not
been FDA-approved for severe S. aureus infections [69].
One reason for failure in severe infections might be the
amount of thymidine released from damaged host tissues
and bacteria, a concept strengthened by the fact that S.
aureus thermonuclease releases thymidine from DNA. Thy-
midine antagonizes the antistaphylococcal effects of both
trimethoprim and sulfamethoxazole, the two compounds of
co-trimoxazole. Thus, failure with co-trimoxazole may well
Table 1 Antibiotic treatment of chronic implant-free osteomyelitis (concomitant to surgery if no surgical removal in toto; personal suggestions)
Parenteral treatment Oral treatment
Antibiotic Alternatives Duration Antibiotic Alternatives Durationp
Methicillin-resistant
staphylococci
Vancomycina Teicoplaninc 0–2 weeks Fusidic acidg + rifampinb Ciprofloxacinh + rifampinb 6–12 weeks
Daptomycinn 0–2 weeks Levofloxacini + rifampinb 6–12 weeks
Tigecyclined 0–2 weeks Doxycyclink + rifampinb 6–12 weeks
Linezolide 0–2 weeks Minocyclinl + rifampinb 6–12 weeks
Ceftobripolef 0–2 weeks Cotrimoxazolem + rifampinb 6–12 weeks
Methicillin-sensitive
staphylococci and other
Gram-positives
Cephalosporins of
1st or 2nd generation,
Vancomycina 0–2 weeks Clindamycinep Ciprofloxacinh + rifampinb 6–12 weeks
Daptomycinn 0–2 weeks Levofloxacini (+ rifampinb) 6–12 weeks
Penicillins 0–2 weeks Cotrimoxazolem + rifampinb 6–12 weeks
Gram-negatives Ceftriaxon Ceftriaxone 0–2 weeks Ciprofloxacinh 6–12 weeks
Ceftazidime 0–2 weeks Levofloxacini 6–12 weeks
Cefepime 0–2 weeks
Anaerobes Amoxicillin-clavulanate Carbapenems 0–2 weeks Metronidazoleq Clindamycinep 6–12 weeks
a Vancomycin: 2×15 mg/kg iv or 30 mg/kg/d in continuous infusion. Targeted serum vancomycinemia in steady state: ~25 mg/L
b Rifampin: 600–1,200 mg/d. Parenteral medication not necessary. Always in combination, never alone (development of resistance)
In absence of implants, rifampin is not indicated, but may be used in combination therapy because of good bone penetration
c Teicoplanin: 1st day 2×400 mg intravenously. From 2nd day 1×400 mg iv. It can also be given by intramuscular route
d Tigecycline: 100 mg iv once, thereafter 2×50 mg/d iv. Mostly experimental so far
e Linezolid: 2×600 mg/d. In non-bacteremic cases, linezolid can be given orally. Be aware of interactions with MAO-inhibitors, myelosuppression,
and polyneuropathy
f Ceftobripole: 2–3×500 mg/d. No studies for osteomyelitis thus far
g Fusidic acid: 3×500 mg/d. Always in combination (possible development of resistance during monotherapy)
h Ciprofloxacin: 2×500 mg/d in combination, 2×750 mg in monotherapy
i Levofloxacin: 2×500 mg/d
k Doxycyclin: 2×100 mg/d
l Minocyclin: 2×100 mg/d
m Cotrimoxazole: 2 double-strength tablets (800 mg trimethroprim, 160 mg sulfadiaxozide) per day. May have failure when high inoculums.
Eventually 3 × double-strength tablets per day
n Daptomycine: 6–10 mg/kg/d once daily. Few data on human osteo-articular infections available
p Clindamycine: 3×600 mg/d
q Metronidazole: 3×500 mg/d
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depend on the amount of tissue damage and organism bur-
den [70].
Tetracyclines (doxycycline and minocycline; both 100 mg
bid) are lipophilic, facilitating the passage into tissues. Evi-
dence exists essentially for skin and soft-tissue infections, but
unfortunately not much for osteomyelitis. Tetracyclines are
often combined with rifampin, although firm data are lacking
[71, 72].
Oral fusidic acid 500 mg tid has demonstrated effi-
cacy in chronic osteomyelitis [73]. Most experts [74] do
not recommend monotherapy, because of development
of resistance [75]. The time delay under current therapy
until the appearance of resistance is unknown and might
be variable. The antibiotic can be combined with rifam-
pin [76]. Fusidic acid is available in some (not all)
European countries, but not in the United States [38].
Streptogramins such as quinupristin-dalfopristin (IV) or
pristinamycin (oral) inhibit protein synthesis by binding to
bacterial ribosomes. Quinupristin-dalfopristin administra-
tion requires central venous access and dextrose infusion
[38] and is not frequently used.
For anaerobic, streptococcal, and staphylococcal
clindamycine-sensitive osteomyelitis, bacterial protein
synthesis inhibition by clindamycin 600–900 mg tid is
an option [20••]. The clinical efficacy of clindamycin in
bone infection can be explicated by its excellent penetration
despite its classification as a bacteriostatic agent [45•].
Although staphylococci may be susceptible to fosfo-
mycin and chloramphenicol and despite their excellent
tissue penetration, these antibiotics have not been much
approved for osteo-articular infections [77]. Physicians
fear agranulocytosis under chloramphenicol medication.
For anaerobic osteomyelitis, metronidazole is the drug
of choice [14], as are quinolones [12, 20••, 78] for
Gram-negative infection. Quinolones are the only avail-
able class for Gram-negative infections in oral form and
are, therefore, precious. Pseudomonas aeruginosa and
other nonfermenting Gram-negative rods may rapidly
develop resistance in monotherapy. Therefore, a combi-
nation with another parenteral drug or prolonged IV
treatment in pseudomonal osteomyelitis would be wise,
but no antibiotic treatment adapted for this situation has
been studied, to the best of our knowledge. Of note, the
optimal oral dose for ciprofloxacin for bone and syno-
vial infections is set at 750 mg bid [1, 20••, 37••, 44,
79••, 80] for patient with a good renal function. Cipro-
floxacin can “cure” staphylococcal osteomyelitis also in
monotherapy [20••, 44], but probably fewer streptococ-
cal infections. Indeed, a meta-analysis including seven
studies and 411 patients reported equivalence in the
remission rates of osteomyelitis treated with quinolones,
as compared with beta-lactam antibiotics [12]. We
would preserve this medication for combined treatment
with rifampin or for resistant Gram-negative pathogens
[12].
Local Antibiotic-Releasing Delivery Systems
The ideal local antibiotic delivery system is lacking [81].
Available systems release antibiotics locally at concentra-
tions exceeding up to 1,000 times those of the minimum
inhibitory concentrations for the most common pathogens
without releasing in the systemic circulation [82]. However,
the duration of time over which these antibiotics continue to
be active is less certain. Gentamicin, the most frequently
used antibiotic compound, may theoretically lead to devel-
opment of small colony variants [64]. It is unknown whether
local antibiotic delivery could be equivalent to systemic
antibiotics. Only a few available data suggest an equivalent
remission rate up to 78 % in osteomyelitis patients treated
with beads alone [83]. The major disadvantage of local
beads is the presumed need for surgical removal [82].
Outcomes and Variables Associated with Treatment
Failures
Recurrences of osteomyelitis after several years, if not dec-
ades, have been reported [84]. Many experts advocate that if
the bone is infected, it may remain infected throughout life
and even beyond, unless an amputation is performed. Some
authors suggest that “arrest” or “remission” is a more ap-
propriate term than “cure” for defining the outcome in
chronic osteomyelitis [24]. In general, remission rates for
osteomyelitis oscillate from 40 % [80, 85] to a peak of
success around 80 % [1, 37••]. Of note, high remission
reports are often seen in short follow-up times [86] or
among children [33].
In contrast to arthroplasty infection [87], no such epide-
miological studies exist regarding association with recur-
rence risk for inplant-free osteomyelitis. Inadequate
debridement may be the most important reason for failure
[40, 88]. Staphylococcal small-colony variants are further
considered as risk [2, 64]. Previously infected bone must be
considered a lifetime focus of diminished resistance, and
thus former osteomyelitis should be considered a risk factor
for a second episode by another pathogen at the same site,
due to altered bone surfaces [84]. Further reported variables
associated with treatment failure are smoking [17, 89], older
age [89], distal tibia osteomyelitis [17], or duration of dis-
charge before treatment [17, 88].
It is an unresolved topic if the pathogen itself increases
the likelihood of treatment failure in implant-free osteomy-
elitis. Sparse and heterogeneous data suggest that P. aerugi-
nosa might be more associated with failures than S. aureus
[20••, 90], but this needs confirmation.
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One very rare, but potentially fatal, late-term (after dec-
ades) complication of untreated chronic osteomyelitis is
squamous cell carcinoma [91], also called Marjolin’s ulcer
[91]. The physiopathological mechanism of this transforma-
tion is largely unknown [91], and overall incidence is be-
lieved to be around 0.2 % among all chronic cases of
osteomyelitis [91].
Special Features
Diabetic Foot Osteomyelitis
Clinicians must recognize main differential diagnoses of
diabetic foot osteomyelitis, which are the Charcot foot
[19], gout, and inflammation due to ischemia itself [19,
92•]. In perforating ulcers, there is an underlying oste-
omyelitis in about 15 % [2] to 20 % [93, 94], especially
if the wound extends to bone and joints. According to
an international expert panel, no significant differences
in outcome are associated with any particular treatment
strategy [92•]. There are no data supporting the superi-
ority of any particular delivery route of systemic anti-
biot ics or the optimal therapy durat ion [92•] .
Bioavailable oral antibiotics are sufficient in most mild
and moderate osteomyelitis [92•]. Aerobic Gram-
positive cocci (especially S. aureus) are predominant
[95]. Thus, therapy aimed solely at aerobic Gram-
positive cocci may be sufficient for mild-to-moderate
infections in patients who have not recently received
antibiotic therapy [92•]. Patients with chronic wounds
or those who have recently received antibiotic therapy
may also be infected with Gram-negative rods. Broad-
spectrum empirical therapy takes part of severe infec-
tions. In severe diabetic foot infections, antibiotics are
given initially intravenously to achieve maximal tissue
concentrations in an area already compromised by arte-
riopathy, although no evidence for a superiority of IV
medication exists [92•, 94]. Expert suggestions for the
duration of antibiotic therapy for acute osteomyelitis are
6 weeks [19, 94] and, for chronic infection, are at least
12 weeks [93, 94], if not up to 46 weeks [16, 93]. No
available evidence supports the use of hyperbaric oxy-
gen or granulocyte-colony stimulating factors [92•].
There is no scientific evidence that surgical debridement
of infected bone is routinely necessary in patients without
osseous or articular deformation and pathologic weight
charges due to neuropathy [92•, 95], although surgery is
very convenient, rapidly healing, and superior in most cases,
as compared with conservative approaches. Prolonged
courses of oral antibiotics are, moreover, associated with
an increased risk of diarrhea caused by Clostridium difficile
or emergence of multidrug-resistant organisms [96•].
Conservative success rates have been cited as 75 % [93]
and as 77 % [95] over a median period of follow-up of
2 years [95]. Further research is required to establish the
relative importance of surgical or conservative approaches
[96•].
Sacral Osteomyelitis
This chronic osteomyelitis is related to decubitus in
patients with multiple comorbidities and/or neurologic
disorders. It is perhaps the most difficult osteomyelitis
to treat, since there is no remission because the reason
for chronic osteomyelitis cannot be reversed. In these
chronic decubitus patients, the infected sacral bone often
cannot be excised, and the patient cannot be improved
neurologically. Prevention is of utmost importance.
Thorough daily nursing care, avoiding pressure ulcers
(position changes, specialized beds), and debridement
are the keys to success. In ameliorated cases, plastic
surgeons may graft. The ideal duration of antibiotic
administration is unknown. Since it is a palliative situ-
ation, the authors of this article administer antibiotics
for 2–4 weeks. The aim is not to eradicate bone infec-
tion but to calm it. Clearly, more research is needed is
this field of osteomyelitis.
Conclusion
Chronic osteomyelitis is a multifaceted bacterial infec-
tion that requires surgery for treatment. The duration
and form of concomitant administration of antibiotic
agents are based on expert opinion. The traditional
recommendation of 6–12 weeks of antibiotic therapy,
of which at least the first 2–6 weeks are intravenous,
is more and more challenged in favor of an oral anti-
biotic treatment with selected agents from the start
[20••]. There is no evidence that a total duration of
more than 4–6 weeks improves outcome, when com-
pared with shorter regimens. External advice from an
infectious diseases physician may help to narrow the
initial antibiotic and may further help to reduce antibi-
otic consumption in a cost-effective way [97]. The fu-
ture may eventually bring even shorter regimens in
adults with selected oral agents, since there is already
ongoing research and evidence for pediatric septic ar-
thritis and (acute) osteomyelitis [6••].
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